Author:
Costa F P,de Oliveira A C,Meirelles R,Machado M C C,Zanesco T,Surjan R,Chammas M C,de Souza Rocha M,Morgan D,Cantor A,Zimmerman J,Brezovich I,Kuster N,Barbault A,Pasche B
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De GJ, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (26): 4293–4300
2. Amato D, Pasche B (1993) An evaluation of the safety of low energy emission therapy (published erratum appears in Compr Ther 1994;20(12):681. Compr Ther 19: 242–247
3. Barbault A, Costa F, Bottger B, Munden R, Bomholt F, Kuster N, Pasche B (2009) Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res 28 (1): 51
4. Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M (2007) Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97 (7): 862–867
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42 (5): 1208–1236